John DiPersio
Professor, Medicine · Washington University/B-JH/SLCH Consortium
Credentials: · · · · · · ·
History
Research
Review · Biology of Blood and Marrow Transplantation · 2019 · 3,048 citations
Recurring mutations found by sequencing an acute myeloid leukemia genome
Case report · New England Journal of Medicine · 2009 · 1,846 citations
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
New England Journal of Medicine · 2012 · 1,753 citations
- PW
117 papers · 2 as a fellow
110 papers
73 papers
70 papers · 3 as a fellow
61 papers · 2 as a fellow
- TL
54 papers
52 papers
51 papers
Grants
- 2017–2032
Optimizing Hematopoietic Stem Cell Transplantation For The Treatment Of Hematological Malignancies
National Cancer Institute · R35
Contact PI · $7.8M · Washington University
- 2026–2031
Enhancing CAR-T Cell Therapy for DLBCL
National Cancer Institute · R01
Contact PI · $548.5K · Washington University
- 2013–2029
Specialized Program of Research Excellence (SPORE) in Leukemia
National Cancer Institute · P50
Project lead · $4.7M · Washington University
- 2012–2027
Washington University Paul Calabresi K12 Career Development Award for Clinical Oncology
National Cancer Institute · K12
PI · $11.7M · Washington University
Clinical trials
- 2021–2025
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
Principal investigator · Completed · Phase 1
NeoImmuneTech
- 2020–2022
Principal investigator · Completed · Phase 2
Washington University School of Medicine
- 2020–2021
Ruxolitinib to Combat COVID-19
Principal investigator · Withdrawn · Phase 2
Washington University School of Medicine
- 2020–2022
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
Principal investigator · Completed · Phase 2
Masonic Cancer Center, University of Minnesota